Sign in Subscribe
1 min read Access Landscape

NRDL+ 2024 Annual Executive Debrief: The State of Access for Innovative Medicines in China

NRDL+ 2024 Annual Executive Debrief: The State of Access for Innovative Medicines in China

In this inaugural annual NRDL+ debrief, we comprehensively examined pivotal developments and trends across basic medical insurance schemes, the commercial health insurance sector, and the provider sector. These developments and trends have a significant impact on pricing and access to innovative medicines in China, making this debrief a must-read for anyone interested in the Chinese market.

Section 1: Three key trends based on China's Basic Medical Insurance (BMI) data and their ecosystem implications

Section 2: Basic Medical Insurance: Shift of Funds toward Innovative Medicine

Section 3: Commercial Health Insurance: An Opportunity for Genuine Payment Innovation

Section 4: Provider: Expansion of Payment Reform Aligned with Medical Service Pricing Overhaul


Published by:

Kelly Ke

You might also like...

Apr
30
NRDL+ 2025 Annual Executive Debrief: The State of Access for Innovative Medicines in China

NRDL+ 2025 Annual Executive Debrief: The State of Access for Innovative Medicines in China

This Access360 Executive Briefing lays the groundwork for understanding China’s shift toward value-based pricing, deeper insurance–medicine–care integration, and broader market transformation driven by its national commercial insurance catalog initiatives.
1 min read
Jun
05
Accessing Innovative Orphan Therapies in China: Local Advancements

Accessing Innovative Orphan Therapies in China: Local Advancements

These local initiatives have developed unique early access programs and multi-level funding models for orphan therapies, addressing the core issue of covering high-cost rare disease drugs not included in the national catalog.
3 min read
Apr
10
Former CFDA Head Bi Jingquan: Challenges and Solutions in China's Innovative Medicine Market

Former CFDA Head Bi Jingquan: Challenges and Solutions in China's Innovative Medicine Market

Bi Jingquan, previously at the helm of the China Food and Drug Administration and instrumental in regulatory overhauls that transformed
4 min read
Dec
20
China Market Access Pathways for Innovative Medicines Infographic

China Market Access Pathways for Innovative Medicines Infographic

Breaking from my usual bi-weekly newsletters, I have a valuable resource for you: an infographic detailing China Market Access Pathways
1 min read
Sep
27
Wonder Sir Founder on Pharma Success: The Importance of Early Investment and Trust in China

Wonder Sir Founder on Pharma Success: The Importance of Early Investment and Trust in China

“In my capacity as a researcher, I've had experience in both scientific research and drug development. Additionally, as
6 min read